Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of Lerociclib in Healthy Volunteers
NCT02821624Phase 1Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lerociclib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative) (12 cohorts), sponsored by G1 Therapeutics, Inc. Primary endpoint: Number of Treatment Related Adverse Event, including Abnormal Laboratory Events. Started May 2016; status: completed.
02
Drugs
lerociclib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT02821624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821624.